Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 8;10(11):3821-3841.
doi: 10.1021/acsinfecdis.4c00359. Epub 2024 Oct 22.

High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics

Affiliations

High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics

Brent S Weber et al. ACS Infect Dis. .

Abstract

To cause infection, bacterial pathogens must overcome host immune factors and barriers to nutrient acquisition. Reproducing these aspects of host physiology in vitro has shown great promise for antibacterial drug discovery. When used as a bacterial growth medium, human serum replicates several aspects of the host environment, including innate immunity and iron limitation. We previously reported that a high-throughput chemical screen using serum as the growth medium enabled the discovery of novel growth inhibitors overlooked by conventional screens. Here, we report that a subset of compounds from this high-throughput serum screen display an unexpected growth enhancing phenotype and are enriched for synthetic siderophores. We selected 35 compounds of diverse chemical structure and quantified their ability to enhance bacterial growth in human serum. We show that many of these compounds chelate iron, suggesting they were acting as siderophores and providing iron to the bacteria. For two different pharmacophores represented among these synthetic siderophores, conjugation to the β-lactam antibiotic ampicillin imparted iron-dependent enhancement in antibacterial activity. Conjugation of the most potent growth-enhancing synthetic siderophore with the monobactam aztreonam produced MLEB-22043, a broad-spectrum antibiotic with significantly improved activity against Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa. This synthetic siderophore-monobactam conjugate uses multiple TonB-dependent transporters for uptake into P. aeruginosa. Like aztreonam, MLEB-22043 demonstrated activity against metallo-β-lactamase expressing bacteria, and, when combined with the β-lactamase inhibitor avibactam, was active against clinical strains coexpressing the NDM-1 metallo-β-lactamase and serine β-lactamases. Our work shows that human serum is an effective bacterial growth medium for the high-throughput discovery of synthetic siderophores, enabling the development of novel Trojan Horse antibiotics.

Keywords: Trojan horse antibiotic; antibiotic; high-throughput screening; iron; siderophore; siderophore-conjugate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

References

    1. Murray C. J. L.; Ikuta K. S.; Sharara F.; Swetschinski L.; Robles Aguilar G.; Gray A.; Han C.; Bisignano C.; Rao P.; Wool E.; Johnson S. C.; Browne A. J.; Chipeta M. G.; Fell F.; Hackett S.; Haines-Woodhouse G.; Kashef Hamadani B. H.; Kumaran E. A. P.; McManigal B.; Achalapong S.; Agarwal R.; Akech S.; Albertson S.; Amuasi J.; Andrews J.; Aravkin A.; Ashley E.; Babin F.-X.; Bailey F.; Baker S.; Basnyat B.; Bekker A.; Bender R.; Berkley J. A.; Bethou A.; Bielicki J.; Boonkasidecha S.; Bukosia J.; Carvalheiro C.; Castañeda-Orjuela C.; Chansamouth V.; Chaurasia S.; Chiurchiù S.; Chowdhury F.; Clotaire Donatien R.; Cook A. J.; Cooper B.; Cressey T. R.; Criollo-Mora E.; Cunningham M.; Darboe S.; Day N. P. J.; De Luca M.; Dokova K.; Dramowski A.; Dunachie S. J.; Duong Bich T.; Eckmanns T.; Eibach D.; Emami A.; Feasey N.; Fisher-Pearson N.; Forrest K.; Garcia C.; Garrett D.; Gastmeier P.; Giref A. Z.; Greer R. C.; Gupta V.; Haller S.; Haselbeck A.; Hay S. I.; Holm M.; Hopkins S.; Hsia Y.; Iregbu K. C.; Jacobs J.; Jarovsky D.; Javanmardi F.; Jenney A. W. J.; Khorana M.; Khusuwan S.; Kissoon N.; Kobeissi E.; Kostyanev T.; Krapp F.; Krumkamp R.; Kumar A.; Kyu H. H.; Lim C.; Lim K.; Limmathurotsakul D.; Loftus M. J.; Lunn M.; Ma J.; Manoharan A.; Marks F.; May J.; Mayxay M.; Mturi N.; Munera-Huertas T.; Musicha P.; Musila L. A.; Mussi-Pinhata M. M.; Naidu R. N.; Nakamura T.; Nanavati R.; Nangia S.; Newton P.; Ngoun C.; Novotney A.; Nwakanma D.; Obiero C. W.; Ochoa T. J.; Olivas-Martinez A.; Olliaro P.; Ooko E.; Ortiz-Brizuela E.; Ounchanum P.; Pak G. D.; Paredes J. L.; Peleg A. Y.; Perrone C.; Phe T.; Phommasone K.; Plakkal N.; Ponce-de-Leon A.; Raad M.; Ramdin T.; Rattanavong S.; Riddell A.; Roberts T.; Robotham J. V.; Roca A.; Rosenthal V. D.; Rudd K. E.; Russell N.; Sader H. S.; Saengchan W.; Schnall J.; Scott J. A. G.; Seekaew S.; Sharland M.; Shivamallappa M.; Sifuentes-Osornio J.; Simpson A. J.; Steenkeste N.; Stewardson A. J.; Stoeva T.; Tasak N.; Thaiprakong A.; Thwaites G.; Tigoi C.; Turner C.; Turner P.; van Doorn H. R.; Velaphi S.; Vongpradith A.; Vongsouvath M.; Vu H.; Walsh T.; Walson J. L.; Waner S.; Wangrangsimakul T.; Wannapinij P.; Wozniak T.; Young Sharma T. E. M. W.; Yu K. C.; Zheng P.; Sartorius B.; Lopez A. D.; Stergachis A.; Moore C.; Dolecek C.; Naghavi M. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022, 399 (10325), 629–655. 10.1016/S0140-6736(21)02724-0. - DOI - PMC - PubMed
    1. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. https://www.who.int/publications/i/item/9789240093461 (accessed July 24, 2024).
    1. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. https://www.who.int/publications-detail-redirect/9789240047655 (accessed 2024-04–24).
    1. Hornef M. W.; Wick M. J.; Rhen M.; Normark S. Bacterial Strategies for Overcoming Host Innate and Adaptive Immune Responses. Nat. Immunol. 2002, 3 (11), 1033–1040. 10.1038/ni1102-1033. - DOI - PubMed
    1. Carfrae L. A.; Brown E. D. Nutrient Stress Is a Target for New Antibiotics. Trends Microbiol. 2023, 31 (6), 571–585. 10.1016/j.tim.2023.01.002. - DOI - PubMed

LinkOut - more resources